BAX 855, a PEGylated rFVIII product with prolonged half-life

Summary

A longer acting recombinant FVIII is expected to serve patients’ demand for a more convenient prophylactic therapy. We have developed BAX 855, a PEGylated form of Baxter’s rFVIII product ADVATE^™ based on the ADVATE^™ manufacturing process. The conjugation process for preparing BAX 855 uses a novel PEG reagent. The production process was adjusted to yield a rFVIII conjugate with a low PEGylation degree of about 2 moles PEG per FVIII molecule. This optimised modification degree resulted in an improved PK profile for rFVIII without compromising its specific activity. PEGylation sites were identified by employing various HPLC- and MS-based methods. These studies not only indicated that about 60% of the PEG chains are localised to the B-domain, which is cleaved off upon physiological activation during the coagulation process, but also demonstrated an excellent lot to lot consistency with regard to PEGylation site distribution. Detailed biochemical characterization further showed that PEGylated FVIII retained all the physiological functions of the FVIII molecule with the exception of binding to the LRP clearance receptor which was reduced for BAX 855 compared to ADVATE^™. This might provide an explanation for the prolonged circulation time of BAX 855 as reduced receptor binding might slow-down clearance. Preclinical studies showed improved pharmacokinetic behaviour and clinically relevant prolonged efficacy compared to ADVATE^™ without any signs of toxicity or elevated immunogenicity. The comprehensive preclinical data package formed the basis for approval of the phase 1 clinical study by European authorities which started in 2011.

Keywords

Recombinant factor VIII - PEG - haemophilia - substitution therapy

• References

• 1 MASAC Recommendation Concerning Prophylaxis (Prophylactic Administration of Clotting Factor Concentrate to Prevent Bleeding). 3–8–2007. National Hemophilia Foundation. www.hemo philia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=5&contentid=349.
• 2 MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). 11–4–2007. National Hemophilia Foundation. www.hemophilia.org/ NHFWeb/MainPgs/MainNHF.aspx?menuid=5&contentid=349.
• 3 Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients--a longterm follow-up. J Intern Med 1997; 241: 395-400.
• 4 Royal S, Schramm W, Berntorp E. et al. Quality-oflife differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 08: 44-50.
• 5 Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 433-440.
• 6 Manco-Johnson M. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. Haemophilia 2007; 13 (Suppl. 02) 4-9.
• 7 Roosendaal G, Lafeber F. Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit. N Engl J Med 2007; 357: 603-605.
• 8 Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
• 9 Morado M, Villar A, Jimenez-Yuste V. et al. Prophylactic treatment effects in inhibitor risk: experience in one centre. Haemophilia 2005; 11: 79-83.
• 10 Lee CA. Prevention of haemophilic synovitis: prophylaxis. Haemophilia 2007; 13 (Suppl. 03) 20-25.
• 11 Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
• 12 Manco-Johnson MJ, Nuss R, Geraghty S. et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-117.
• 13 Fischer K, van der Bom JG, Molho P. et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and longterm outcome. Haemophilia 2002; 08: 745-752.
• 14 Berntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia 2009; 15: 1219-1227.
• 15 Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-832.
• 16 Björkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years: A population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-998.
• 17 Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 02: 214-221.
• 18 Riley T, Riggs-Sauthier J. The benefits of challenges of PEGylating small molecules. Pharm Tech 2008; 32: 1-5.
• 19 Bovenschen N, Boertjes RC, van Stempvoort G. et al. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem 2003; 278: 9370-9377.
• 20 Bovenschen N, van Stempvoort G, Voorberg J. et al. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding site for low-density lipoprotein receptor-related protein within the A2 domain. J Thromb Haemost 2006; 04: 1487-1493.
• 21 Bovenschen N, Mertens K, Hu L. et al. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 2005; 106: 906-912.
• 22 Mei B, Pan C, Jiang H. et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-279.
• 23 Rottensteiner H, Turecek PL, Meijer AB. et al. The prolonged half-life of PEGylated and polysialylated FVIII in murine models might be caused by a reduced binding to the LRP1 receptor. 52. Jahres- tagung der Gesellschaft für Thrombose- und Hämostaseforschung e.V. February 20–23, 2008. Wiesbaden; Germany.:
• 24 Monetti C, Rottensteiner H, Gritsch H. et al. Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGE. Electrophoresis 2011; 32: 1292-1301.
• 25 Elödi S, Váradi K, Vörös E. Kinetic of formation of factor IXa – factor VIII complex on the surface of platelets. Thromb Res 1981; 21: 695-700.
• 26 Fay PJ. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb Haemost 1999; 82: 193-200.
• 27 Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-20145.
• 28 Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-1243.
• 29 Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipid vesicles. J Biol Chem 1990; 265: 815-822.
• 30 Muchitsch EM, Turecek PL, Zimmermann K. et al. Phenotypic expression of murine hemophilia. Thromb Haemost 1999; 82: 1371-1373.
• 31 Bi L, Lawler AM, Antonarakis SE. et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia. A. Nat Genet 1995; 10: 119-121.
• 32 Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005; 115: 3355-3362.
• 33 Bendetowicz AV, Wise RJ, Gilbert GE. Collagenbound von Willebrand factor has reduced affinity for factor VIII. J Biol Chem 1999; 274: 12300-12307.